Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $13.00 price target on the stock.
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis [Yahoo! Finance]
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
Trump's crypto advocacy steers businesses away from traditional treasury assets [Yahoo! Finance Canada]
Trump's crypto advocacy steers businesses away from traditional treasury assets [Yahoo! Finance Canada]